Deciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 12-Month High at $17.73

Deciphera Pharmaceuticals (NASDAQ: DCPH) reached a new 12-month high of $17.73 on August 19, 2021. The company is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare genetic diseases.

Deciphera's stock has been performing well in recent months, with its share price increasing by over 50% since the beginning of the year. This growth can be attributed to several factors, including the successful completion of clinical trials for its lead product, Triflunomide, which is being developed as a treatment for a rare genetic disorder called triplet repeat expansion disorders.

In addition to Triflunomide, Deciphera has several other promising therapies in development, including a potential treatment for another rare genetic disease called Duchenne muscular dystrophy. The company's strong pipeline and focus on rare diseases have made it an attractive investment opportunity for both individual investors and institutional investors.

Overall, Deciphera Pharmaceuticals' recent stock performance is a positive sign for the company and its continued growth in the biopharmaceutical industry.